$1.73
3.89% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US36269B1052
Symbol
GANX
Sector
Industry

Gain Therapeutics Inc Stock price

$1.73
-0.20 10.36% 1M
+0.10 6.14% 6M
-0.43 19.91% YTD
-0.16 8.47% 1Y
-9.27 84.27% 5Y
-9.27 84.27% 10Y
-9.27 84.27% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.07 3.89%
ISIN
US36269B1052
Symbol
GANX
Sector
Industry

Key metrics

Market capitalization $51.81m
Enterprise Value $43.17m
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 8.60
Free Cash Flow (TTM) Free Cash Flow $-19.11m
Cash position $9.07m
P/E forward negative
Short interest 1.02%

Is Gain Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Gain Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Gain Therapeutics Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Gain Therapeutics Inc forecast:

Buy
100%

Financial data from Gain Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.70 9.70
10% 10%
-
- Research and Development Expense 11 11
8% 8%
-
-20 -20
9% 9%
-
- Depreciation and Amortization 0.08 0.08
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
9% 9%
-
Net Profit -20 -20
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gain Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gain Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C.
Neutral
GlobeNewsWire
16 days ago
BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada.
Neutral
GlobeNewsWire
about one month ago
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025 First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected Mid-2025
More Gain Therapeutics Inc News

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Head office United States
CEO Gene Mack
Employees 31
Founded 2017
Website www.gaintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today